Brokerages predict that Rocket Pharmaceuticals Inc (NASDAQ:RCKT) will report ($0.50) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Rocket Pharmaceuticals’ earnings. The business is expected to report its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Rocket Pharmaceuticals will report full year earnings of ($1.76) per share for the current fiscal year, with EPS estimates ranging from ($1.90) to ($1.61). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.48) per share, with EPS estimates ranging from ($3.05) to ($1.91). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that cover Rocket Pharmaceuticals.
Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.04).
Several research analysts recently weighed in on RCKT shares. Zacks Investment Research lowered Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. LADENBURG THALM/SH SH started coverage on Rocket Pharmaceuticals in a research report on Thursday. They issued a “buy” rating for the company. William Blair started coverage on Rocket Pharmaceuticals in a research report on Wednesday, August 8th. They issued a “buy” rating for the company. Finally, ValuEngine upgraded Rocket Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $27.00.
A number of institutional investors have recently modified their holdings of RCKT. Strs Ohio purchased a new position in Rocket Pharmaceuticals in the second quarter worth approximately $119,000. Essex Investment Management Co. LLC purchased a new position in Rocket Pharmaceuticals in the second quarter worth approximately $306,000. Cobblestone Capital Advisors LLC NY purchased a new position in Rocket Pharmaceuticals in the second quarter worth approximately $353,000. State of Wisconsin Investment Board purchased a new position in Rocket Pharmaceuticals in the second quarter worth approximately $391,000. Finally, Rhumbline Advisers purchased a new position in Rocket Pharmaceuticals in the second quarter worth approximately $398,000. Institutional investors own 85.03% of the company’s stock.
Shares of NASDAQ:RCKT traded down $1.05 during midday trading on Friday, hitting $24.44. The company had a trading volume of 460,809 shares, compared to its average volume of 145,903. Rocket Pharmaceuticals has a twelve month low of $4.88 and a twelve month high of $25.96. The company has a quick ratio of 13.27, a current ratio of 13.27 and a debt-to-equity ratio of 0.25.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development.
Featured Article: Diversification For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.